One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study

Table 2

Change in VA score from baseline to last visit (on-treatment population, 𝑛=370^†).

	VA at baseline mean±SD median (range)	VA at last visit mean±SD median (range)	Change from baseline to last visit mean±SD; median (range)	Improved (change ≥15 letters/3 lines); 𝑁 (%)	Stable; (change <15 letters/3 lines); 𝑁 (%)	Deterioration (change ≥15 letters/3 lines); 𝑁 (%)
All patients	58.3±12.2; 60 (7–86)	59.3±16.2; 61 (1–90)	1.0±13.6; 1 (−38–56)	54 (14.7%)	273 (74.4%)	40 (10.9%)
<80 years (𝑁=195)	59.6±11.1; 60 (30–85)	61.6±14.8; 63 (16–90)	2.1±12.8; 3 (−37–36)	33 (16.9%)	146 (74.9%)	16 (8.2%)
≥80 years (𝑁=172)	56.8±13.1; 60 (7–86)	56.6±17.3; 59 (1–88)	−0.2±14.5; 0 (−38–56)	21 (12.2%)	127 (73.8%)	24 (14.0%)
Female (𝑁=245)	58.5±11.6; 60 (17–86)	60.3±14.8; 62 (1–88)	1.9±12.4; 3 (−38–39)	35 (14.3%)	190 (77.6%)	20 (8.2%)
Male (𝑁=122)	57.9±13.2; 60 (7–85)	57.2±18.7; 60 (5–90)	−0.7±15.7; 0 (−38–56)	19 (15.6%)	83 (68.0%)	20 (16.4%)
Baseline VA ≤ median (𝑁=179)	48.2±8.3; 50 (7–59)	51.8±16.2; 53 (1–83)	3.5±15.2; 4 (−37–56)	40 (22.3%)	120 (67.0%)	19 (10.6%)
Baseline VA > median (𝑁=188)	67.8±6.0; 67 (60–86)	66.4±12.7; 69 (23–90)	−1.4±11.5; −1 (−38–21)	14 (7.4%)	153 (81.4%)	21 (11.2%)
Retrospectively recruited (𝑁=203)	58.2±12.0; 60 (7–86)	60.1±15.6; 61 (5–88)	1.9±13.5; 2 (−37–56)	32 (15.8%)	153 (75.4%)	18 (8.9%)
Prospectively recruited (𝑁=164)	58.4±12.3; 60 (21–84)	58.3±17.0; 61 (1–90)	−0.1±13.7; 0.5 (−38–33)	22 (13.4%)	120 (73.2%)	22 (13.4%)

^†Data not available for 3 patients.